| 书目名称 | Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag | | 副标题 | Proceedings of the N | | 编辑 | Joel Morganroth,E. Neil Moore | | 视频video | | | 丛书名称 | Developments in Cardiovascular Medicine | | 图书封面 |  | | 描述 | The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall s | | 出版日期 | Conference proceedings 1989 | | 关键词 | artery; cardiovascular; drugs; myocardial infarction; sudden cardiac death | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-4613-1605-3 | | isbn_softcover | 978-1-4612-8888-6 | | isbn_ebook | 978-1-4613-1605-3Series ISSN 0166-9842 | | issn_series | 0166-9842 | | copyright | Kluwer Academic Publishers 1989 |
The information of publication is updating
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag影响因子(影响力)
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag影响因子(影响力)学科排名
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag网络公开度
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag网络公开度学科排名
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag被引频次
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag被引频次学科排名
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag年度引用
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag年度引用学科排名
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag读者反馈
书目名称Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Ag读者反馈学科排名
|
|
|
发表于 2025-3-21 19:01:31
